natgillin/translations-raw huggingface dataset:
PritorPlus should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile. 
Zdravila PritorPlus ne smemo dajati bolnikom s holestazo, z obolenji z zaporo žolčevoda ali močno zmanjšanim delovanjem jeter (glejte poglavje 4.3), ker se telmisartan v glavnem izloča z žolčem.
PritorPlus tablets are for once-daily oral administration and should be taken with liquid, with or without food. 
Jemanje tablet PritorPlus je peroralno enkrat na dan s tekočino, s hrano ali brez nje.
If any of the above applies to you, tell your doctor or pharmacist before taking PritorPlus. 
Če imate katero od naštetih stanj, povejte zdravniku ali farmacevtu preden boste vzeli zdravilo PritorPlus.
The risk of hypokalaemia is greater in patients with cirrhosis of liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or Adrenocorticotropic hormone (ACTH) (see section 4.5). 
Možnost, da se bo hipokaliemija pojavila, je večja pri bolnikih z jetrno cirozo, s povečano diurezo ali pri bolnikih, ki peroralno ne dobivajo ustreznih odmerkov elektrolitov, in pri sočasnem zdravljenju s kortikosteroidi ali adrenokortikotropnim hormonom (ACTH) (glejte poglavje 4.5).
MARKETING AUTHORISATION NUMBER(S) EU/1/02/215/015-021 
EU/1/02/215/015-021
Conversely, due to the antagonism of the angiotensin II (AT1) receptors by the telmisartan component of PritorPlus, hyperkalaemia might occur. 
Zaradi antagonističnega delovanja telmisartana v zdravilu PritorPlus na receptorje za angiotenzin II (AT1) je možna tudi hiperkaliemija.
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.901.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo. 
Telmisartan je učinkoval podobno kot ramipril na vnaprej opredeljeni sekundarni opazovani dogodek, ki je zajemal srčnožilno smrt, neusodni miokardni infarkt in neusodno možgansko kap [0,99 (97,5odstotni IZ 0,90 do 1,08), p (enakovrednost) = 0,0004], in je bil primarni opazovani dogodek v referenčni raziskavi HOPE (The Heart Outcome Prevention Evaluation Study), v kateri so ramipril primerjali s placebom.
Concomitant administration of hydrochlorothiazide and telmisartan does not appear to affect the pharmacokinetics of either substance in healthy subjects. 
Kaže, da sočasno dajanje hidroklorotiazida in telmisartana pri zdravih osebah ne spremeni farmakokinetike ene ali druge učinkovine.
Try to take a tablet at the same time each day. 
Priporočeni odmerek je ena tableta na dan. Poskusite tablete jemati vsak dan ob isti uri.
As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. 
Enako kot za uporabo drugih vazodilatatorjev velja posebna previdnost pri dajanju zdravila PritorPlus bolnikom z zožitvijo aorte ali mitralne zaklopke ali obstruktivno hipertrofično kardiomiopatijo.
Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 - 1.5 h after dosing. 
Telmisartan: Telmisartan doseže po peroralnem dajanju največjo koncentracijo v 0,5 do 1,5 ure.
Patients were randomized to one of the three following treatment groups: telmisartan 80 mg (n = 8542), ramipril 10 mg (n = 8576), or the combination of telmisartan 80 mg plus ramipril 10 mg (n = 8502), and followed for a mean observation time of 4.5 years. 
Bolnike so naključno razvrstili v tri skupine, ki so prejemale telmisartan po 80 mg (n = 8542), ramipril po 10 mg (n = 8576) ali kombinacijo telmisartana po 80 mg in ramiprila po 10 mg (n = 8502).
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine) The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide. 
Nedepolarizirajoči mišični relaksanti s perifernim delovanjem (npr. tubokurarin) Hidroklorotiazid lahko poveča učinek nedepolarizirajočih relaksantov skeletnih mišic.
3: For further description, please see sub-section “Description of selected adverse reactions” Hydrochlorothiazide: 
3: Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov« Hidroklorotiazid
If PritorPlus is used during breast feeding, doses should be kept as low as possible. 
Če doječe matere zdravilo PritorPlus uporabljajo med dojenjem, morajo biti njegovi odmerki karseda majhni.
In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8). 
Če sta žilni tonus in delovanje ledvic pretežno odvisna od delovanja renin-angiotenzinaldosteronskega sistema (npr. pri bolnikih s hudim kongestivnim srčnim popuščanjem ali ledvično boleznijo, tudi zožitvijo ledvične arterije), povezujejo zdravljenje z drugimi zdravili, katera delujejo na ta sistem, z akutno hipotenzijo, s hiperazotemijo, oligurijo in, redko, z akutno ledvično odpovedjo (glejte poglavje 4.8).
Increased incidence of sepsis has been observed with telmisartan only, however can not be ruled out for PritorPlus. 
Kljub temu, da so povečano pojavnost opazili pri samostojni uporabi telmisartana, je med jemanjem zdravila PritorPlus ni možno izključiti.
Based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of the above medicinal products may lead to increases in serum potassium and is, therefore, not recommended (see section 
Izkušnje z drugimi zdravili, ki zavirajo delovanje renin-angiotenzinskega sistema, kažejo, da lahko sočasno dajanje teh zdravil poveča raven kalija v serumu, in jih zato ne priporočamo (glejte poglavje 4.4).
Investigations Not known: 
Preiskave Neznana:
PritorPlus fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide and 80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone. 
Zdravilo PritorPlus, fiksna kombinacija (40 mg telmisartana/12,5 mg hidroklorotiazida in 80 mg telmisartana/12,5 mg hidroklorotiazida), je indicirano za odrasle, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim telmisartanom.
PritorPlus is a combination of an angiotensin II receptor antagonist, telmisartan, and a thiazide diuretic, hydrochlorothiazide. 
Zdravilo PritorPlus je kombinacija antagonista receptorjev angiotenzina II telmisartana in tiazidnega diuretika hidroklorotiazida.
PritorPlus is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when telmisartan is used alone. 
Zdravilo PritorPlus je namenjeno za zdravljenje visokega krvnega tlaka (esencialne hipertenzije) pri odraslih, pri katerih s samim telmisartanom krvnega tlaka ne moremo dovolj uravnati.
How to take PritorPlus 
Kako jemati zdravilo PritorPlus
PritorPlus should be kept in the sealed blister due to the hygroscopic property of the tablets. 
Zdravilo PritorPlus je treba shranjevati v zaprtem pretisnem omotu, ker so tablete higroskopične.
1: Based on post-marketing experience 2: For further description, please see sub-section “Description of selected adverse reactions” 
2: Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov«
MARKETING AUTHORISATION NUMBER(S) PritorPlus 40 mg/12.5 mg tablets EU/1/02/215/001-005, 011, 013 
PritorPlus 40 mg/12,5 mg tablete EU/1/02/215/001-005, 011, 013
There is no experience regarding the administration of PritorPlus in patients with recent kidney transplantation. 
Z uporabo zdravila PritorPlus pri bolnikih z nedavno presajeno ledvico ni izkušenj.
Thiazide-induced hypokalaemia or hypomagnesaemia favours the onset of digitalis-induced arrhythmia (see section 4.4). 
Hipokaliemija ali hipomagneziemija, ki jo povzročajo tiazidi, poveča možnost nastanka aritmije, inducirane z digitalisom (glejte poglavje 4.4).
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). 
Podatki kliničnih preskušanj so pokazali, da je dvojna blokada sistema renin-angiotenzin-aldosteron (RAAS) s hkratno uporabo zaviralcev ACE, blokatorjev receptorjev angiotenzina II ali aliskirena povezana z večjo pogostnostjo neželenih učinkov, npr. hipotenzije, hiperkaliemije in zmanjšanega delovanja ledvic (vključno z akutno odpovedjo ledvic) kot uporaba enega samega zdravila,ki deluje na RAAS (glejte poglavja 4.3, 4.4. in 5.1).
What PritorPlus contains 
Kaj vsebuje zdravilo PritorPlus
Previous preclinical safety studies performed with co-administration of telmisartan and hydrochlorothiazide in normotensive rats and dogs, in doses producing exposure comparable to that in the clinical therapeutic range, caused no additional findings not already observed with administration of either substance alone. 
Predhodne predklinične raziskave o varnosti, v katerih so telmisartan in hidroklorotiazid sočasno dajali normotenzivnim podganam in psom, odmerki, ki so ustrezali tistim v kliničnem terapevtskem razponu, niso imeli učinkov, ki bi se razlikovali od onih, ki so znani za posamezni snovi.
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)]. 
Pri pojavnosti primarnega, sestavljenega opazovanega dogodka (kot so srčnožilna smrt, neusodni miokardni infarkt, neusodna možganska kap ali bolnišnično zdravljenje zaradi zastojnega srčnega popuščanja) med skupinama ni bilo statistično značilne razlike [15,7 % v skupini s telmisartanom in 17,0 % v skupini s placebom ob razmerju ogroženosti 0,92 (95-odstotni IZ 0,81 do 1,05, p = 0,22)].
Co-administration of lithium and PritorPlus is not recommended (see section 4.4). 
Sočasno dajanje litija in zdravila PritorPlus ne priporočamo (glejte poglavje 4.4).
• PritorPlus 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Pritor 40 mg 
• Zdravilo PritorPlus 40 mg/12,5 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno nadzorovati z zdravilom Pritor 40 mg
The overall incidence of adverse reactions reported with PritorPlus was comparable to those reported with telmisartan alone in randomised controlled trials involving 1471 patients randomised to receive telmisartan plus hydrochlorothiazide (835) or telmisartan alone (636). 
V kliničnih preskušanjih je sodelovalo 1471 bolnikov, ki so bili naključno razvrščeni v skupini, od katerih je ena prejemala telmisartan in hidroklorotiazid (835), druga pa samo telmisartan (636).
Presumably through blockade of the reninangiotensin-aldosterone system, co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics. 
Sočasno dajanje telmisartana domnevno deluje zaradi blokade renin-angiotenzinaldosteronskega sistema, reverzibilno na izgubo kalija, do katere prihaja pri teh diuretikih.
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13). 
Pri zdravljenju s telmisartanom je bilo razmerje ogroženosti v primerjavi z ramiprilom 1,01 (97,5-odstotni IZ 0,93 do 1,10, p (enakovrednost) = 0,0019 pri mejni vrednosti 1,13).
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (See section 5.3). 
Znano je, da izpostavljenost antagonistom angiotenzina II v drugem in tretjem trimesečju nosečnosti lahko povzroči fetotoksične učinke pri človeku (zmanjšano delovanje ledvic, oligohidramnij, zapoznela zakostenitev lobanje) in toksične učinke pri novorojenčku (ledvična odpoved, hipotenzija, hiperkaliemija) (glejte poglavje 5.3).
(It is also better to avoid PritorPlus in early pregnancy 
• če ste noseči več kot 3 mesece (zdravilu PritorPlus se je bolje izogibati tudi v zgodnji nosečnosti
In a double-blind controlled clinical trial (n=687 patients evaluated for efficacy) in non-responders to the 80 mg/12.5 mg combination, an incremental blood pressure lowering effect of the 80 mg/25 mg combination compared to continued treatment with the 80 mg/12.5 mg combination of 2.7/1.6 mm Hg (SBP/DBP) was demonstrated (difference in adjusted mean changes from baseline). 
V dvojno slepi, nadzorovani klinični raziskavi (n = 687 bolnikov, pri katerih so ocenili učinkovitost) pri bolnikih, ki se niso odzivali na zdravljenje s kombinacijo 80 mg/12,5 mg, je kombinacija 80 mg/25 mg v primerjavi s stalnim zdravljenjem s kombinacijo 80 mg/12,5 dodatno znižala krvni tlak za 2,7/1,6 mm Hg (SKT/DKT) (razlika v prilagojenih srednjih spremembah glede na izhodiščno vrednost).
These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking PritorPlus. 
Oba sta lahko tudi simptoma zvišanega očesnega tlaka, ki se pojavita nekaj ur do nekaj tednov po začetku jemanja zdravila PritorPlus.
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)]. 
Podatki dokazujejo korist zdravljenja s telmisartanom v primerjavi s placebom na podlagi njegovega učinka na vnaprej opredeljen sekundarni, sestavljeni opazovani dogodek, ki je zajemal srčnožilno smrt, neusodni miokardni infarkt in neusodno možgansko kap [0,87 (95-odstotni IZ 0,76 do 1,00, p = 0,048)].
In preclinical safety studies performed with co-administration of telmisartan and hydrochlorothiazide in normotensive rats and dogs, doses producing exposure comparable to that in the clinical therapeutic range caused no additional findings not already observed with administration of either substance alone. 
Predklinične raziskave o varnosti, v katerih so telmisartan in hidroklorotiazid sočasno dajali normotenzivnim podganam in psom, odmerki, ki so ustrezali tistim v kliničnem terapevtskem razponu, niso imeli učinkov, ki bi se razlikovali od onih, ki so znani za posamezni snovi.
• PritorPlus 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Pritor 80 mg 
• Zdravilo PritorPlus 80 mg/12,5 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno nadzorovati z zdravilom Pritor 80 mg
Pack sizes: - Blister with 14, 28, 30, 56, 90, or 98 tablets or - Perforated unit dose blisters with 28 x 1 tablets. 
Velikost pakiranja: - pretisni omot po 14, 28, 30, 56, 90 ali 98 tablet ali - perforirani pretisni omoti za enkratni odmerek po 28 x 1 tableto.
In patients with mild to moderate hepatic impairment the posology should not exceed PritorPlus 40 mg/12.5 mg once daily. 
Odmerek za bolnike z blago do zmerno zmanjšanim jetrnim delovanjem ne sme prekoračiti odmerka zdravila PritorPlus 40 mg/12,5 mg 1-krat na dan.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Unit dose blister (28x1 tablets pack) or any non 7 count blister 
Perforiran pretisni omot za enkratni odmerek (28 x 1 tableta) ali vsi tisti pretisni omoti, ki ne vsebujejo po 7 tablet
EU/1/02/215/015 14 tablets EU/1/02/215/016 28 tablets EU/1/02/215/017 28 x 1 tablets EU/1/02/215/018 30 tablets EU/1/02/215/019 56 tablets EU/1/02/215/020 90 tablets EU/1/02/215/021 98 tablets 
EU/1/02/215/015 14 tablet EU/1/02/215/016 28 tablet EU/1/02/215/017 28 x 1 tableta EU/1/02/215/018 30 tablet EU/1/02/215/019 56 tablet EU/1/02/215/020 90 tablet EU/1/02/215/021 98 tablet
Adverse reactions reported with one of the individual components may be potential adverse reactions with PritorPlus, even if not observed in clinical trials with this product. 
Neželeni učinki, o katerih so poročali za eno od posameznih sestavin, se lahko pojavijo tudi pri zdravilu PritorPlus, četudi jih v kliničnem preskušanju tega zdravila niso zasledili.
In a pooled analysis of two similar 8 week double-blind placebo-controlled clinical trials vs. valsartan/hydrochlorothiazide 160 mg/25 mg (n=2121 patients evaluated for efficacy) a significantly greater blood pressure lowering effect of 2.2/1.2 mm Hg (SBP/DBP) was demonstrated (difference in adjusted mean changes from baseline, respectively) in favour of telmisartan/hydrochlorothiazide 80 mg/25 mg combination. 
V analizi združenih podatkov iz dveh podobnih 8-tedenskih, dvojno slepih, s placebom nadzorovanih kliničnih raziskav, v katerih je bilo primerjano zdravilo kombinacija valsartan/hidroklorotiazid 160 mg/25 mg (n = 2121 bolnikov, pri katerih so ocenili učinkovitost), je bilo znižanje krvnega tlaka pri kombinaciji telmisartan/hidroklorotiazid 80 mg/25 mg značilno večje, in sicer za 2,2/1,2 mm Hg (SKT/DKT) (razlika v prilagojenih srednjih spremembah glede na izhodiščno vrednost).
PritorPlus is also available at the dose strengths 40 mg/12.5 mg and 80 mg/12.5 mg Renal impairment 
Zdravilo PritorPlus je na voljo tudi v jakosti 40 mg/12,5 mg in 80 mg/12,5 mg. Ledvična okvara
How to store PritorPlus 
Shranjevanje zdravila PritorPlus
PritorPlus is available in blisters packs containing 14, 28, 30, 56, 90 or 98 tablets, or unit dose blister packs containing 28 x 1 tablets. 
Zdravilo PritorPlus je na voljo v pretisnih omotih po 14, 28, 30, 56, 90, 98 tablet ali pretisnih omotih za enkratni odmerek po 28 x 1 tableta.
Periodic monitoring of serum potassium and ECG is recommended when PritorPlus is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics) and the following torsades de pointes inducing medicinal products (which include some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes. 
Priporočamo periodično spremljanje ravni kalija v serumu in EKG, kadar dajemo zdravilo PritorPlus hkrati z zdravili, na delovanje katerih vplivajo motnje serumskega kalija (npr. z glikozidi digitalisa ali antiaritmiki).
INFORMATION IN BRAILLE PritorPlus 80 mg/25 mg 
PODATKI V BRAILLOVI PISAVI PritorPlus 80 mg/25 mg
Lupus-like syndrome, photosensitivity reactions, skin vasculitis, 
lupusu podoben sindrom, fotosenzibilne reakcije, kožni vaskulitis, toksična epidermalna nekroliza, multiformni eritem
- Hypokalaemia 
Hipokaliemija
NAME OF THE MEDICINAL PRODUCT PritorPlus 80 mg/25 mg tablets 
IME ZDRAVILA PritorPlus 80 mg/25 mg tablete
INFORMATION IN BRAILLE PritorPlus 40 mg/12.5 mg 
PODATKI V BRAILLOVI PISAVI PritorPlus 40 mg/12,5 mg
EU/1/02/215/001 14 tablets EU/1/02/215/002 28 tablets EU/1/02/215/003 28 x 1 tablets EU/1/02/215/013 30 tablets EU/1/02/215/004 56 tablets EU/1/02/215/011 90 tablets EU/1/02/215/005 98 tablets 
EU/1/02/215/001 14 tablet EU/1/02/215/002 28 tablet EU/1/02/215/003 28 x 1 tableta EU/1/02/215/013 30 tablet EU/1/02/215/004 56 tablet EU/1/02/215/011 90 tablet EU/1/02/215/005 98 tablet
The other ingredients are lactose monohydrate, magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone, red iron oxide (E172), sodium hydroxide, sodium starch glycollate (type A), sorbitol (E420). 
Druge sestavine zdravila so laktoza monohidrat, magnezijev stearat, koruzni škrob, meglumin, mikrokristalna celuloza, povidon (K25), rdeč železov oksid (E172), natrijev hidroksid, natrijev karboksimetilškrob (vrsta A) in sorbitol (E420).
- Hyponatraemia and hypochloraemic alkalosis There is no evidence that PritorPlus would reduce or prevent diuretic-induced hyponatraemia. 
Ni podatkov, ki bi kazali, da zdravilo PritorPlus zmanjša ali prepreči hiponatriemijo, ki jo povzročajo diuretiki.
EU/1/02/215/006 14 tablets EU/1/02/215/007 28 tablets EU/1/02/215/008 28 x 1 tablets EU/1/02/215/014 30 tablets EU/1/02/215/009 56 tablets EU/1/02/215/012 90 tablets EU/1/02/215/010 98 tablets 
EU/1/02/215/006 14 tablet EU/1/02/215/007 28 tablet EU/1/02/215/008 28 x 1 tableta EU/1/02/215/014 30 tablet EU/1/02/215/009 56 tablet EU/1/02/215/012 90 tablet EU/1/02/215/010 98 tablet
Protect your skin from sun exposure and UV rays while taking PritorPlus. 
Med jemanjem zdravila PritorPlus zaščitite kožo pred izpostavljenostjo soncu in UV-žarkom.
The other ingredients are lactose monohydrate, magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone, yellow iron oxide (E172), sodium hydroxide, sodium starch glycollate (type A), sorbitol (E420). 
Druge sestavine zdravila so laktoza monohidrat, magnezijev stearat, koruzni škrob, meglumin, mikrokristalna celuloza, povidon (K25), rumen železov oksid (E172), natrijev hidroksid, natrijev karboksimetilškrob (vrsta A) in sorbitol (E420).
PritorPlus fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on PritorPlus 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. 
Zdravilo PritorPlus, fiksna kombinacija (80 mg telmisartana in 25 mg hidroklorotiazida), je indicirano za odrasle, pri katerih krvnega tlaka ne moremo ustrezno uravnati z zdravilom PritorPlus 80 mg/12,5 mg (80 mg telmisartana in 12,5 mg hidroklorotiazida) ali za bolnike, ki jemljejo telmisartan in hidroklorotiazid posebej in imajo ustaljen krvni tlak.
PritorPlus 80 mg/12.5 mg tablets Each tablet contains 80 mg telmisartan and 12.5 mg hydrochlorothiazide. 
PritorPlus 80 mg/12,5 mg tablete Ena tableta vsebuje 80 mg telmisartana in 12,5 mg hidroklorotiazida.
PritorPlus 40 mg/12.5 mg tablets Each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide. 
PritorPlus 40 mg/12,5 mg tablete Ena tableta vsebuje 40 mg telmisartana in 12,5 mg hidroklorotiazida.
Talk to your doctor before taking PritorPlus: 
Pred začetkom jemanja zdravila PritorPlus se posvetujte z zdravnikom:
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 80 mg telmisartan and 25 mg hydrochlorothiazide. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Enatableta vsebuje 80 mg telmisartana in 25 mg hidroklorotiazida.
PritorPlus 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by PritorPlus 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. 
• Zdravilo PritorPlus 80 mg/25 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno uravnati z zdravilom PritorPlus 80 mg/12,5 mg, ali bolnikom, ki jemljejo telmisartan in hidroklorotiazid posebej in imajo ustaljen krvni tlak.
INFORMATION IN BRAILLE PritorPlus 80 mg/12.5 mg 
PODATKI V BRAILLOVI PISAVI PritorPlus 80 mg/12,5 mg
The overall incidence and pattern of adverse reactions reported with PritorPlus 80 mg/25 mg was comparable with PritorPlus 80 mg/12.5 mg. A dose-relationship of adverse reactions was not established and they showed no correlation with gender, age or race of the patients. 
Celokupna pogostnost in vzorec neželenih učinkov, o katerih so poročali v zvezi z zdravilom PritorPlus 80 mg/25 mg, je primerljiva s pogostnostjo neželenih učinkov zdravila PritorPlus 80 mg/12,5 mg.